Peptide Analog N-Terminal Acylation PEGylation CLR/RAMP
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic candidates for targeting CLR/RAMP receptors have efficacy or safety concerns, such as short half-lives, low potencies, receptor-specificity, liver toxicity, and limited access to central nervous system targets.
Innovation Solution
Development of adrenomedullin and intermedin/adrenomedullin 2 analogs with N-terminal acylation and/or polyethylene glycol (PEG) moieties, which exhibit superagonistic or superantagonistic activity on CLR/RAMP receptors, enhancing receptor-activation activities and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic candidates target CLR/RAMP receptors, then receptor activation is achieved, but half-life is short and potency is low
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of adrenomedullin and intermedin analogs through N-terminal acylation and PEGylation. These chemical modifications alter the pharmacokinetic parameters of the peptides, extending their half-life while maintaining receptor activation efficacy. The acylation and PEGylation processes change the molecular properties of the peptides to improve their stability and circulation time.
Solution Approach 2:
The patent creates composite peptide structures by combining adrenomedullin or intermedin core sequences with N-terminal acyl groups and PEG moieties. This composite approach integrates multiple functional elements: the peptide core provides receptor binding activity, while the acylation and PEGylation add stability and extended half-life characteristics, achieving both high potency and prolonged duration of action.
2Reliability
If existing therapeutic candidates target CLR/RAMP receptors, then receptor activation is achieved, but liver toxicity occurs
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of the peptide therapeutics through N-terminal acylation and PEGylation. These changes alter how the peptides are metabolized and cleared from the body, reducing accumulation in the liver and minimizing hepatotoxicity while maintaining effective receptor activation. The modifications optimize the balance between efficacy and safety profile.
3Reliability
If existing therapeutic candidates target CLR/RAMP receptors, then peripheral effects are achieved, but access to central nervous system targets is limited
Solution Approach 1:
The patent creates universal peptide therapeutics through N-terminal acylation and PEGylation that can access multiple tissue compartments including the central nervous system. These modifications enhance blood-brain barrier penetration and allow the same peptide backbone to exert effects at both peripheral and central targets, providing multi-functional activity for treating diverse conditions.
Data Source
AI summary
Analogs for CLR/RAMP receptor ligands are provided that have agonist, superagonist, antagonist, super-antagonist, or multiple receptor modulatng activity. The analogs can be selective for one or more CLR/RAMP receptors, or can be pan-specific for multiple G protein-coupled receptors.